Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future

W A Breeman1, M de Jong, D J Kwekkeboom

  • 1Department of Nuclear Medicine, Erasmus Medical Centre Rotterdam, The Netherlands. breeman@nuge.azr.nl

European Journal of Nuclear Medicine
|October 5, 2001
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Salvage peptide receptor radionuclide therapy with [<sup>177</sup>Lu-DOTA,Tyr<sup>3</sup>]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours.

European journal of nuclear medicine and molecular imaging·2018
Same author

Evaluation of a new immunoassay for chromogranin A measurement on the Kryptor system.

Practical laboratory medicine·2017
Same author

Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors.

European journal of nuclear medicine and molecular imaging·2015
Same author

Radiolabeled gastrin/CCK analogs in tumor diagnosis: towards higher stability and improved tumor targeting.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...·2015
Same author

Gene transcript analysis blood values correlate with ⁶⁸Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status.

European journal of nuclear medicine and molecular imaging·2015

Somatostatin receptor imaging and therapy are valuable for neuroendocrine tumors. This review covers receptor subtypes, expression in tumors, and advances in radiolabeled somatostatin analogues for diagnosis and treatment.

Area of Science:

  • Nuclear medicine
  • Oncology
  • Radiopharmaceutical science

Background:

  • Somatostatin receptor scintigraphy is established for visualizing neuroendocrine tumors (NETs) and metastases.
  • Radiolabeled somatostatin analogues offer a new avenue for receptor-mediated therapy in NETs.

Purpose of the Study:

  • To review the basic science and current knowledge of somatostatin receptor subtypes and their expression in NETs.
  • To discuss novel somatostatin analogues, chelators, and radionuclides for imaging and therapy.
  • To explore limitations and future perspectives in somatostatin receptor-mediated applications.

Main Methods:

  • Literature review of basic science, historical background, and current research.
  • Discussion of somatostatin receptor subtypes and their role in NETs.

Related Experiment Videos

  • Analysis of new developments in radiolabeled somatostatin analogues and radionuclides.

    • Main Results:

    • Somatostatin receptor-mediated imaging is a key diagnostic tool for NETs.
    • Emerging radiolabeled analogues show promise for targeted somatostatin receptor-mediated therapy.
    • Advancements in analogues, chelators, and radionuclides are expanding therapeutic options.

    Conclusions:

    • Somatostatin receptor-mediated approaches are crucial for both diagnosing and treating neuroendocrine tumors.
    • Continued research into novel analogues and radionuclides will further enhance imaging and therapeutic efficacy.
    • Addressing current limitations is essential for optimizing future clinical applications.